Pfizer COVID-19 vaccine protective against SARS-CoV-2 varian

 E-Mail
Washington, D.C. - June 9, 2021 - The Pfizer COVID-19 vaccine is protective against several SARS-CoV-2 variants that have emerged, according to new research presented in the journal
mBio, an open-access journal of the American Society for Microbiology. While this is good news, the study also found that the only approved monoclonal antibody therapy for SARS-CoV-2 might be less effective against SARS-CoV-2 variants in laboratory experiments.
"The vaccines provide very strong protection against the earlier forms of the virus as well as the newer variants. This is an important point because I have heard people say that they don't think there is a reason to get vaccinated, because the vaccine isn't going to work against the variants, but that is not true--the vaccine will work against the variants," said Nathaniel "Ned" Landau, Ph.D., professor in the Department of Microbiology at the NYU Grossman School of Medicine, in New York City.

Related Keywords

Brazil , New York , United States , Denmark , United Kingdom , Washington , South Africa , Ohio , Spain , Brazilian , South African , American , Nathaniel Ned Landau , American Society For Microbiology , Regeneron Pharmaceuticals , Department Of Microbiology , Grossman School Of Medicine , Langone Vaccine Center , American Society , Vaccine Center , Columbus Ohio , Biology , Icrobiology , பிரேசில் , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , டென்மார்க் , ஒன்றுபட்டது கிஂக்டம் , வாஷிங்டன் , ஓஹியோ , ஸ்பெயின் , பிரேசிலியன் , அமெரிக்கன் , அமெரிக்கன் சமூகம் க்கு நுண்ணுயிரியல் , துறை ஆஃப் நுண்ணுயிரியல் , மொத்த மனிதர் பள்ளி ஆஃப் மருந்து , லன்கொனே தடுப்பூசி மையம் , அமெரிக்கன் சமூகம் , தடுப்பூசி மையம் , கொலம்பஸ் ஓஹியோ , உயிரியல் ,